Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae in sera from patients with acute salpingitis

PER-ANDERS MÅRDH,* INGA LIND,† LARS SVENSSON,‡ LARS WESTRÖM,‡ AND BIRGER R MÖLLER§

From the *Institute of Medical Microbiology, University of Lund, Sweden; the †Neisseria Department, Statens Serum Institut, Copenhagen, Denmark; the ‡Department of Gynaecology and Obstetrics, University Hospital, Lund, Sweden; and the §Institute of Medical Microbiology, University of Aarhus, Denmark

SUMMARY Paired sera from 60 consecutive patients with acute salpingitis, confirmed by laparoscopy, were examined for serum antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae. By a microimmunofluorescence (MIF) test IgM or IgG antibodies to C trachomatis or both were present in sera from 80% of the patients; by indirect haemagglutination (IHA) tests antibodies to M hominis and N gonorrhoeae pilar antigens were present in 40% and 18% respectively. In a control group of 50 pregnant women antibodies to the same three organisms occurred in 8%, 8%, and 6%. Evidence of current chlamydial infection was found in 35 (58%) and of current gonococcal infection in five (8%) of the 60 patients by culture or serological tests or both. The results of chlamydial antibody tests correlated with the severity of the tubal inflammation (as shown by laparoscopy) and the duration of the lower abdominal pain before attendance. The predictive values of a positive and a negative MIF test result were 44% and 83% respectively and of the IHA gonococcal antibody test 36% and 100% respectively. Significant rises in titre of antibodies to M hominis were found in 12% of patients. A four-fold or greater rise in titre indicated probable double infections with chlamydia and mycoplasmas in 7% of patients. Thus, at present gonococcal salpingitis appears to form only a small proportion of all cases of salpingitis in Southern Sweden, and in patients with nongonococcal salpingitis infections with C trachomatis and M hominis commonly occur.

Introduction

Although there are diverse opinions1,2 on the proportion of acute salpingitis that is caused by Neisseria gonorrhoeae, most workers agree that other agents can also be responsible for this condition. Nongonococcal salpingitis may be caused by a variety of organisms, the relative importance of which, however, seems to vary in different regions.

Some workers3-5 have proposed that gonococcal infections account for the vast majority of tubal infections. Others have presented evidence that nongonococcal salpingitis is at least as common as gonococcal salpingitis in their hospital catchment areas6-9 and that the proportion of nongonococcal cases has increased during the last decade.7,10

We have shown that Chlamydia trachomatis7,11-13 and Mycoplasma hominis8,14,15 are agents that may cause nongonococcal pelvic inflammatory disease (PID). In the present study, we tested paired sera from consecutive patients with acute salpingitis for antibodies to C trachomatis by an indirect immunofluorescence test and for antibodies to M hominis and N gonorrhoeae by indirect haemagglutination tests.

Patients and methods

STUDY POPULATION

The series of patients with salpingitis were 60 consecutive cases treated at the department of

Address for reprints: Dr P-A Mårdh, Institute of Medical Microbiology, University of Lund, Solvegatan 23, S-223 62 Lund, Sweden

Accepted for publication 7 October 1980

obstetrics and gynaecology at the University Hospital, Lund, Sweden, and were verified by laparoscopy;16; 19 cases were classified as severe, 25 as moderately severe, and 16 as mild. Paired sera were obtained; the time elapsing between the collection of the two specimens varied from four to 60 days (mean 15·7 days). The ages of the patients varied from 14 to 48 years (mean 23·5 years). Ten of the patients had had one previous episode of salpingitis and one had had more than one.

CONTROLS
Sera from 50 pregnant women attending consecutively from the same hospital catchment area served as controls. Their ages ranged from 17 to 38 years (mean 23·8 years). Whether any of these women had previously had salpingitis was not known.

SEROLOGY
A modified microimmunofluorescence (MIF) test17 using three pools of antigen of C trachomatis—immunotypes A-C, D-K (except J), and LGV 1-3—was used to demonstrate both IgM and IgG antibodies.

Antibodies to M hominis were detected by an indirect haemagglutination test, which was in principle performed as described by Krogsgaard-Jensen.18 The antigen was prepared from strain D188 of M hominis, which had been isolated from the cervix of a patient with acute salpingitis. After centrifugation of sonically treated cells, the supernatant fluid was used to sensitise formalised sheep erythrocytes.

Gonococcal antibodies were determined by an indirect haemagglutination (IHA) test, using pilar antigens prepared from two strains of N gonorrhoeae.19

In the microimmunofluorescence tests, titres of >16 (IgM) and >32 (IgG) were considered to give positive results for antibodies to C trachomatis, while titres >40 were considered to give positive results in both indirect haemagglutination tests.

CULTURE
The techniques used for the isolation and identification of C trachomatis and N gonorrhoeae were those described.11 Cervical specimens were cultured for C trachomatis and cervical, urethral, and rectal specimens for N gonorrhoeae. Cultures for M hominis were not regularly performed and no cultures were performed for the control group.

PREDICTIVE VALUES AND STATISTICAL CALCULATION
The predictive values (for the diagnosis of chlamydial and gonococcal infection) for positive and negative test results by the MIF test (IgG) and by the IHA test for gonococcal pilar antibodies were calculated as described.20 Kendall’s Tau-C test* was used to determine the correlation between the severity of the tubal inflammatory changes, the duration of pelvic pain before attendance, and the MIF titre to C trachomatis on admission. In these determinations patients who seroconverted or had at least a four-fold rise in titre of IgM or IgG antibodies or both or had an IgM titre of >32 or IgG titre of >512 or both were considered to have a current chlamydial infection.

Results

ANTIBODY TITRES
The maximum titres for each patient of IgM and IgG antibodies to C trachomatis and of antibodies to M hominis and N gonorrhoeae are shown in tables I and II. Antibodies (IgG or IgM or both) to C trachomatis were detected in 80% of the patients and antibodies to M hominis and N gonorrhoeae in 40% and 18% respectively. IgM antibodies to C trachomatis occurred in 12 and IgG antibodies in all 48 seropositive patients. A significant change in antibody titre to C trachomatis occurred in 40% of the patients (21 with IgG, one with IgM, and two with both antibodies), to M hominis in 12%, and to N gonorrhoeae in 5% (table III).

The predictive values for a positive and a negative MIF test result were 44% and 83% respectively; those for the IHA gonococcal pilar antibody test were 36% and 100% respectively. These calculations were based on the assumption that the diagnosis of a current infection was equivalent to a positive culture result for the organism.

CULTURE AND SEROLOGY
The results of cultural and serological studies are compared in table IV. None of the 12 patients with IgM antibodies to C trachomatis was culture-positive for gonococci. Evidence of a current infection (culture-positive or significant change of antibody titre or both) with C trachomatis and N gonorrhoeae occurred in 35 (58%) and five (8%) respectively. Of the 23 patients with positive cultures for chlamydia 17, five, and one had titres of <64, 128-256, and >512 respectively. Ten had a significant rise in the titre of antichlamydial IgG antibodies.

The four patients who harboured gonococci were all in the group of 11 patients who had IHA pilar antibodies to N gonorrhoeae. Two of the three patients with a significant rise in titre harboured gonococci.

*In these calculations the diagnosis of chlamydial and gonococcal infection was based on the result of cultures from the lower genital tract.
Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae

### TABLE I
Maximum MIF test titres of IgM and IgG antibodies to Chlamydia trachomatis in 60 patients with acute salpingitis

<table>
<thead>
<tr>
<th>Ig class</th>
<th>&lt;8</th>
<th>16</th>
<th>32</th>
<th>64</th>
<th>128</th>
<th>256</th>
<th>512</th>
<th>1024</th>
<th>2048</th>
<th>4096</th>
<th>8192</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>48</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>G</td>
<td>11</td>
<td>1</td>
<td>5</td>
<td>14</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TABLE II
Maximum titres of antibodies to Mycoplasma hominis and Neisseria gonorrhoeae in 60 patients with acute salpingitis

<table>
<thead>
<tr>
<th>Organism</th>
<th>No of patients with maximum antibody titre:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤20</td>
</tr>
<tr>
<td>M hominis</td>
<td>36</td>
</tr>
<tr>
<td>N gonorrhoeae</td>
<td>49</td>
</tr>
</tbody>
</table>

### TABLE III
Number and percentage of 60 patients with salpingitis showing antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae

<table>
<thead>
<tr>
<th>Organism</th>
<th>Static</th>
<th>Increased†</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia trachomatis</td>
<td>26 (43)</td>
<td>22 (37)</td>
<td>48 (80)</td>
</tr>
<tr>
<td>Mycoplasma hominis</td>
<td>17 (28)</td>
<td>7 (12)</td>
<td>24 (40)</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>8 (13)</td>
<td>3 (5)</td>
<td>11 (18)</td>
</tr>
</tbody>
</table>

* IgM or IgG or both
† Significantly

### TABLE IV
Comparison of results of culture for C trachomatis and N gonorrhoeae and of serological tests on 60 patients with acute salpingitis

<table>
<thead>
<tr>
<th>Culture result</th>
<th>MIF* test result</th>
<th>No (%) of patients with antibody titre:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>±</td>
<td>No of patients‡</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>-</td>
<td>37</td>
<td>27</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>48</td>
</tr>
</tbody>
</table>

* IgG antibodies
† Gonococcal pilar antibodies
‡ Specimens (cervical) cultured for C trachomatis
§ Specimens (urethral, cervical and rectal) cultured for N gonorrhoeae

### Controls
Antibodies to C trachomatis, M hominis and N gonorrhoeae were demonstrated in 8%, 8%, and 6% of the sera from the control group of pregnant women.

### Discussion
The spectrum and relative importance of various aetiopathological agents of acute salpingitis are influenced by such factors as the relative proportion of cases of different severity and the proportion of venereal and iatrogenic cases (for example, tubal infections occurring before curettage, legal abortion, and insertion of an intrauterine contraceptive device). The proportions of patients with primary and repeated tubal infection may influence the outcome of microbiological studies, as may the mean time interval between the onset of symptoms and sampling.

In the present series there was about the same number of mild, moderately severe, and severe cases. Approximately 85% of the cases could be classified as venereal and 20% of the patients had had salpingitis before. As in all series of patients with acute salpingitis, the time between the onset of symptoms and attendance varied considerably (from one day to more than two weeks).

The aetiological pattern of acute salpingitis seems to show geographical differences. The percentage of cases associated with gonorrhoea in recent studies from the USA has been about twice that of similar studies from Europe. A change in the aetiological pattern with time has also been found in Lund, Sweden; in the middle 1960s about every second case of acute salpingitis had gonorrhoea whereas 12 years later less than 10% of all cases were infected with gonococci.

The time interval between collection of the first and second serum specimen from some patients was comparatively short—less than one week. In others, the time between exposure to infection and sampling of sera was fairly long (more than several months in some cases). This, of course, limits the possibility of demonstrating evidence of a current infection by a significant change in titre. With regard to C trachomatis, however, a correlation was found between a positive serological test result, as well as the antibody titre at initial examination, and the duration of the disease before attendance.

Recently developed tests for detecting gonococcal pilar antibodies have proved to be both sensitive and specific. Such antibodies may persist for years in patients treated for gonorrhoea. In the present series, gonorrhoea had been diagnosed earlier in only two patients, and gonococci could be recovered from only four of the 60 patients. Static,

### STATISTICAL ANALYSIS
There was a correlation between the severity of the tubal changes and the results of the MIF tests (P<0·005) and between the duration of pelvic pain before attendance and the results of serological tests (P<0·009).

Four (7%) of the 60 patients had a significant rise in antibody titres to both C trachomatis and M hominis. The three patients with a significant rise in the titre of IHA gonococcal pilar antibodies had no evidence of a current infection with chlamydia or mycoplasmas.
low titres of IHA gonococcal pilar antibodies and negative culture results were found in six patients, suggesting an antibody response to a past rather than to a present gonococcal infection.

Recent experimental studies\(^{24}\) in grivet monkeys indicate that chlamydia, like gonococci, can spread canalicularly to the Fallopian tubes and produce inflammatory changes that are similar to those found in women with gonococcal salpingitis.\(^{25}\) In such parametria and produce parametritis and salpingitis.\(^{26}\)

In the present series of patients 40% had IHA antibodies to \textit{M hominis}, while a significant rise in titre occurred in 12%. Cultures of \textit{M hominis} were not regularly performed, but the serological test results suggest that current mycoplasmal infections had occurred in an appreciable number of the patients studied.

Of the three agents studied, antibodies occurred most often to \textit{C trachomatis} (80%); 37% of patients had a significant rise in titre. In experimental genital infection with \textit{C trachomatis} in grivet monkeys, IgM antibodies to the organism were detectable between one and two weeks after the infection and had disappeared after a further five or six weeks.\(^{27}\) Our experience so far suggests that even in deep-sited genital chlamydial infections in man, serum antibodies to the organism may persist for a limited period, provided adequate antibiotic therapy has been given. For example, patients with salpingitis with high titres of IgM and IgG antibodies to \textit{C trachomatis}, and from whom the organism was recovered from the cervix and the Fallopian tubes (and who were treated with tetracycline), had no detectable antibodies two years later.\(^{27}\) These findings might suggest that the vast majority of our patients in whom antibodies to \textit{C trachomatis} were detected had a current or comparatively recent chlamydial infection.

Chlamydia were isolated more often in those patients with no detectable antibodies and in those with a low (32-64) rather than a high (>128) IgG antibody titre. No chlamydia were cultured from the patients with IgM antibodies to \textit{C trachomatis}. These results indicate that an immune response to \textit{C trachomatis} may result in negative culture results for the organism in cervical specimens. Antibodies in cervical secretions may also have a similar effect.

In the population studied, the serological “background noise” was low; antibodies to \textit{C trachomatis}, \textit{M hominis}, and \textit{N gonorrhoeae} occurred in <8% of the 50 pregnant women tested as controls, who were all inhabitants of Lund. However, in an earlier study of sera from women living in Landskrona in the same county (Skåne), chlamydial antibodies occurred in the cord blood of 25% of the infants of 139 puerperal women.\(^{28}\) In a recent study of 300 consecutive gynaecological patients treated in the same department as the patients with salpingitis \textit{C trachomatis}, \textit{M hominis}, and \textit{N gonorrhoeae} were isolated from the cervix of 6·1%, 23%, and 2·3% respectively (unpublished data).

In the present study serological tests suggested a concomitant current infection with both chlamydia and mycoplasmas in 7% of the 60 patients. None of the few patients with gonorrhoea had evidence of a current infection with either chlamydia or mycoplasmas. In the 300 outpatients referred to above, chlamydia occurred in 13% of the 23% who harboured mycoplasmas and in 29% of those with gonorrhoea. \textit{M hominis} was recovered from 59% of those infected with \textit{N gonorrhoeae}.

This study showed that acute salpingitis in Lund is associated with a current genital chlamydial infection in at least 40% of patients, whereas gonococcal infections at present occur in only a small percentage (8%) of all cases of salpingitis. Acute infections with \textit{M hominis} could be detected in 10-15% of the patients with acute salpingitis in the area.

To obtain optimum conditions for establishing the diagnosis of chlamydial and gonococcal salpingitis, our study indicates that cultures as well as serological tests should be performed.

This study was supported by a grant from the World Health Organisation, by grant 16X-4509 from the Swedish Medical Research Council, and by grant 512-8215 from the Danish Medical Research Council.

References
Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae


Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae in sera from patients with acute salpingitis.

P A Märdh, I Lind, L Svensson, L Weström and B R Møller

doi: 10.1136/sti.57.2.125

Updated information and services can be found at: [http://sti.bmj.com/content/57/2/125](http://sti.bmj.com/content/57/2/125)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)